USCA RIA’s Regeneron Pharmaceuticals REGN Stock Holding History

USCA RIA’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-536	Closed	-$262K	–	468
2020 Q1	$262K	Buy	+536	New	+$221K	0.03%	340

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

USCA RIA's REGN Position: Q2 2020 in Review

USCA RIA sold out of Regeneron Pharmaceuticals (REGN) in Q2 2020, closing a stake of 536 shares — an estimated $262K sold.

USCA RIA first reported a position in REGN in Q1 2020 and held it in 1 quarter. The position peaked at $262K in Q1 2020. 932 funds tracked by Wall St. Rank hold REGN as of Q2 2020.

USCA RIA reported no remaining Regeneron Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
USCA RIA sold 536 Regeneron Pharmaceuticals shares in Q2 2020, an estimated $262K.
USCA RIA first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 1 quarter.
USCA RIA's Regeneron Pharmaceuticals position peaked at $262K in Q1 2020.
932 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2020.

Based on USCA RIA's 13F filing for Q2 2020, filed 13 Aug 2020.